Facio Therapies has shown that one of its lead compounds can reduce the levels of DUX4 in a mouse model. The company now plans to do further testing of its lead candidate before it can move to a clinical trial in 2021.
DUX4 is a protein that is inappropriately produced in facioscapulohumeral muscular dystrophy (FSHD). DUX4 is damaging to muscles and is thought to cause inflammation and muscle wasting in people with FSHD. Scientists believe that reducing its levels could potentially treat the symptoms of the condition.
For more information, please read Facio Therapies’ press release.